Cancer Communications

Papers
(The median citation count of Cancer Communications is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Kindlin‐1 drives early steps of breast cancer metastasis570
389
354
Treatment of Metastatic Cancer by Conferring Immunogenicity to the Apoptotic Bodies of the Primary Tumor301
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”297
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort266
Issue Information238
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation217
Issue Information215
Issue Information171
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma162
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy161
Dysregulated Proline Metabolism Exacerbates Hepatocellular Carcinoma Metastasis via EPRS1-Mediated mRNA Translation153
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity149
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study147
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives146
Current status and perspectives of esophageal cancer: a comprehensive review141
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update134
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h132
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial124
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions114
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer114
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses113
EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer107
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica101
Issue Information97
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of 97
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence96
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward80
p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases74
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer73
Issue Information70
68
68
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity66
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer66
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study66
N 6 ‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastas66
Cover Image, Volume 45, Issue 662
Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2‐mediated increase of SOAT2 RNA methylation62
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma62
Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma61
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials61
Impact of small molecule‐mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism60
FOXO1 or not FOXO1: that is the question60
Issue Information57
First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expression56
Incidence of and survival with bone and soft tissue sarcoma: A nation‐wide study over four decades55
A strong internal promoter drives massive expression of YEATS‐domain devoid MLLT3 transcripts in HSC and most lethal AML55
Ubiquitination in cancer: mechanisms and therapeutic opportunities53
Antitumoral effects of cannabis in Notch1 ‐mutated T‐cell acute lymphoblastic leukemia52
Harnessing chimeric antigen receptor macrophages against solid tumors52
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial51
Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene49
m 6 A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma49
Enhanced selection of people for lung cancer screening using AHRR (cg05575921) or F2RL3 (cg03636183) methy48
Correction to “Circulating tumor cells share RNA modules with early embryo trophectoderm and with metastatic cancer”47
Low household income and income volatility increase risk of lung cancer: A nationwide retrospective cohort study46
Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race‐specific luminal‐basal and microenvironmental differences46
Issue Information45
Development of antibody‐drug conjugates in cancer: Overview and prospects43
An HGF‐dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis43
Breast cancer: an up‐to‐date review and future perspectives42
4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists42
Inhibition of mTOR attenuates the initiation and progression of BRCA1 ‐associated mammary tumors41
Neuroinflammation drives apathy in cancer cachexia41
Vebreltinib for Previously Treated Astrocytoma, IDH -Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with41
circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer40
Genomic information of children with malignant brain tumors for the prediction of length of hospitalization40
Long‐term antibiotic use and risk of hepatocellular carcinoma later in life: a nationwide cohort study of 9.8 million participants40
Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy38
38
N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA38
Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract38
Single‐cell and bulk transcriptomics identifies a tumor‐specific CD36 + cancer‐associated fibroblast subpopulation in colorectal cancer37
Issue Information37
Issue Information37
Knowing nodal Rouviére: the power of human intelligence in toxicity reduction37
Issue Information36
Cover Image, Volume 44, Issue 436
Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China35
Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‐3 study35
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium35
Breaking barriers: Smart vaccine platforms for cancer immunomodulation34
Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms34
DNA methylation signature predicts cancer response to demethylation agents from profiling diverse cancer cell lines32
Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy32
Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins31
Combination of photodynamic therapy and stimulator of interferon genes (STING) agonist inhibits colorectal tumor growth and recurrence31
The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression31
Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis31
Tumor microenvironment signaling and therapeutics in cancer progression31
30
The Ly6g high Neutrophil Subset Dictates Breast Cancer Lung Metastasis via CD8 + T Cell Death30
Ex vivo STAT3 phosphorylation in circulating immune cells: a novel biomarker for early cancer diagnosis and response to anti‐PD‐1 therapy29
A single measurement of fecal hemoglobin concentration outperforms polygenic risk score in colorectal cancer risk assessment29
TOPK Suppresses the CD8 + T Cell Antitumor Immunity via Modulation of IRF5 Expression29
Single‐cell‐eQTL mapping in circulating immune cells reveals genetic regulation of response‐associated networks in lung cancer immunotherapy29
Cover Image, Volume 43, Issue 628
Advanced precision modeling reveals divergent responses of hepatocellular carcinoma to combinatorial immunotherapy28
Issue Information27
Enhancing sensitivity of triple‐negative breast cancer to DNA‐damaging therapy through chemical inhibition of the m6A methyltransferase METTL325
Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study25
Leptin‐mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer25
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors24
Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy24
The regulatory roles and clinical significance of glycolysis in tumor23
Targeting ferroptosis resistance resensitizes metastatic HR + HER2 breast cancer cells to palboc22
Multiplexed CRISPR/Cas9 Editing of Tumor Suppressor Genes in the Mouse Endometrium Recapitulates High-Risk Endometrial Carcinoma22
22
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients22
HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism22
In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high‐throughput personalized drug discovery22
Lysosomal TMEM9‐LAMTOR4‐controlled mTOR signaling integrity is required for mammary tumorigenesis21
Perivascular localized cells commit erythropoiesis in PDGF‐B‐expressing solid tumors21
Real‐world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non‐interventional study in China21
The SARS‐CoV‐2 spike protein induces lung cancer migration and invasion in a TLR2‐dependent manner20
Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer20
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK- Positive Non-Small Cell Lung Cancer20
Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinica20
Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation20
Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors20
Discovery of a novel viroid‐like circular RNA in colorectal cancer19
Unraveling the routes to distant metastases in colorectal cancer: Tumor deposits and lymph node metastases as the gateway19
TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy19
RNA m 1 A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing ONECUT2 mRNA stabil19
TGFBR1*6A and risk for colorectal cancer18
Targeted STAT1 therapy for LZTR1‐driven peripheral nerve sheath tumor18
Transient and DNA‐free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis18
Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma18
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open‐label, multicenter, phase Ib trial18
Smoking, smoking cessation, and survival after cancer diagnosis in 128,423 patients across cancer types17
Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma17
NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma17
Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer17
Issue Information17
Diagnostic value of genetic mutation analysis and mutation profiling of cell‐free DNA in intraocular fluid for vitreoretinal lymphoma17
Cover Image, Volume 43, Issue 1216
Issue Information16
A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations16
Exciting progress in targeted therapy innovation for unresectable stage III EGFR ‐mutated NSCLC: the phase III LAURA study16
Methionine restriction sensitizes cancer cells to immunotherapy15
Issue Information15
Lung cancer risk score for ever and never smokers in China15
Engineering heavy chain antibody‐drug conjugates against solid tumors for a one‐shot kill15
Combating cancer immunotherapy resistance: a nano‐medicine perspective15
The Roles of Protein S -Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potential15
Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study14
14
14
Nicotinamide N‐methyltransferase negatively regulates metastasis‐promoting property of cancer‐associated fibroblasts in lung adenocarcinoma14
Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor‐associated myocarditis14
Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment14
Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity14
Cover Image, Volume 42, Issue 613
Issue Information13
Cover Image, Volume 43, Issue 913
Transcription factor ETV4 promotes the development of hepatocellular carcinoma by driving hepatic TNF‐α signaling13
Vascular smooth muscle cell plasticity in the tumor microenvironment13
Plasma small‐extracellular vesicles enriched in miR‐122‐5p promote disease aggressiveness in pediatric anaplastic large‐cell lymphoma13
Lymphatic metastasis in non‐small cell lung cancer: recent discoveries and novel therapeutic targets13
Dynamic epi‐transcriptomic landscape mapping with disease progression in estrogen receptor‐positive breast cancer13
Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer12
Training the synergy between Bacillus Calmette‐Guérin and immune checkpoint‐blocking antibodies in bladder cancer12
MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response12
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 202312
CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer12
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy11
Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors11
Effectiveness of Lung Cancer Screening by Sex and Tumor Histology: Extended, Pooled Analysis of the ITALUNG and LUSI Trials, with Comparison to Findings in the NLST11
Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD4711
Issue Information11
WTAP-Mediated Glutaminase Splicing Bias Suppresses Ferroptosis in Hepatocellular Carcinoma11
Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced 11
Transcriptome‐wide association analysis identified candidate susceptibility genes for nasopharyngeal carcinoma11
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy11
KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer11
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial10
Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross‐over pharmacokinetic drug‐drug interaction study10
Vitamin D 3 for reducing mortality from cancer and other outcomes before, during and beyond the COVID‐19 pandemic: A plea for harvesting low‐hanging 10
Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma10
Tumor derived cell‐free nucleic acid upregulates programmed death‐ligand 1 expression in neutrophil via intracellular Toll‐like receptor signaling10
Cover Image, Volume 42, Issue 810
NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4‐acetylated LAMB3‐mediated FAK/ERK pathway10
Dietary intake of advanced glycation endproducts (AGEs) and cancer risk across more than 20 anatomical sites: A multinational cohort study10
Issue Information10
Unveiling quality of clinical trial in China: from concern to confirmation9
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib9
Survival trends of patients with non‐metastatic gastric adenocarcinoma in the US and European countries: the impact of decreasing resection rates9
Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome‐wide association and whole genome sequencing analyses9
A practical overview and statistical analysis of interval‐censored data in cancer9
Cover Image, Volume 42, Issue 69
Cover Image, Volume 43, Issue 119
Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells9
The interplay between natural killer cells and pancreatic stellate cells in pancreatic ductal adenocarcinoma8
A serum exosomal microRNA‐based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma8
Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection8
Hyperprogression after immune checkpoint inhibitors: a cloudy phenomenon with real-life consequences.8
miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies8
Issue Information8
Endopharyngeal Ultrasound-Guided Transpharyngeal Needle Aspiration for Confirming Retropharyngeal Lymph Nodes’ Metastasis among Nasopharyngeal Carcinoma Patients8
Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a “hit‐and‐run” paradigm8
A non‐metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11‐mediated CD133 stability8
Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3‐dependent necroptotic inflammation8
8
Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor8
8
Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21‐mediated ubiquitination/degradation of STAT1 in a GTP binding‐dependent modality8
Issue Information7
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy7
NAT10‐mediated ac 4 C‐modified ANKZF1 promotes tumor progression and lymphangiogenesis in clear‐cell renal cell carcinoma by attenuating YWHAE‐driven7
Single‐cell transcriptomic analysis uncovers intratumoral heterogeneity and drug‐tolerant persister in ALK ‐rearranged lung adenocarcinoma7
Issue Information7
Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis7
7
Single‐cell multi‐omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK‐positive lung cancer7
Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL‐1β and the inflammasome pathway7
Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors7
Non‐small cell lung cancer in China7
Evaluation of exposure‐response‐safety relationship of model‐informed low‐dose 500 mg abiraterone acetate in prostate cancer patients7
Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response6
Targeted reactivation of the novel tumor suppressor DAPK1, an upstream regulator of p53, in high‐grade serous ovarian cancer by mRNA liposomes reduces viability and enhances drug sensitivity in precli6
Issue Information6
Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy6
6
Rescue of p53 functions by in vitro‐transcribed mRNA impedes the growth of high‐grade serous ovarian cancer6
“Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity6
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies6
Issue Information6
Activation mechanisms of clinically distinct B‐Raf V600E and V600K mutants6
Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors6
Unraveling the effects of screening colonoscopy on colorectal cancer early detection and prevention: the NordICC trial revisited6
Cover Image, Volume 45, Issue 126
Exposure of benzo[a]pyrene induces HCC exosome‐circular RNA to activate lung fibroblasts and trigger organotropic metastasis6
Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy6
SALIRI‐based (raltitrexed plus irinotecan) therapy as a second‐line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non‐interventional, registry study6
Multi‐omic study to unmask genes involved in prostate cancer development in a multi‐case family6
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor6
6
Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II s5
Immunosuppressive JAG2 + tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector re5
Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis5
Epigenomic exploration of disease status of EGFR ‐mutated non‐small cell lung cancer using plasma cell‐free DNA hydroxymethylomes5
Older adults living with gastrointestinal cancers in 20215
Aerobic glycolysis promotes tumor immune evasion and tumor cell stemness through the noncanonical function of hexokinase 25
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors5
Issue Information5
A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic5
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions5
Low‐dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma5
0.32936406135559